Tesamorelin & Muscle Mass: IGF-1, Lean Tissue and the Falutz/Stanley Data — UAE Research Guide (2026)

Why Tesamorelin Is Anabolic At All

Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH 1–44). It does not deliver GH itself. Instead, it binds pituitary GHRH receptors and provokes the somatotrophs to release endogenous GH in physiological pulses. Those pulses circulate, reach hepatocytes, and upregulate hepatic IGF-1 production. IGF-1 is the downstream mediator of nearly every classical “growth hormone” anabolic effect in skeletal muscle: satellite-cell activation, mTOR signalling, protein synthesis bias over breakdown, and amino-acid uptake (Klausen 2000; Müller 1999).

That mechanism is the reason a peptide marketed primarily for HIV-associated visceral adiposity (the indication Theratechnologies pursued for FDA approval in 2010) keeps showing up in lean-mass readouts. Where IGF-1 rises, muscle is the obligate beneficiary.

The Falutz 2010 Lean-Mass Signal

Falutz et al. published the pivotal 26-week phase 3 trial of tesamorelin 2 mg/day SC in 410 HIV-positive subjects with abdominal lipohypertrophy (J Clin Endocrinol Metab, 2010). The headline outcome was a 15.2% reduction in visceral adipose tissue versus a 5.0% increase in placebo. The often-overlooked secondary outcome: lean body mass rose by 1.3 kg in the tesamorelin arm, while the placebo arm lost lean tissue. Trunk lean tissue specifically gained 0.7 kg.

This is not a noise signal. The lean-mass change was statistically significant (p<0.001) and dose-correlated with IGF-1 SDS (standard deviation score) elevation. Subjects whose IGF-1 rose into the upper-normal range gained more lean tissue than those who remained mid-range. The dose-response is precisely what you would predict if hepatic IGF-1 were the anabolic mediator.

The Stanley 2014 Extension

Stanley et al. (J Clin Endocrinol Metab, 2014) extended observation to 52 weeks and added precise body-composition measurement with DEXA. Findings of interest for muscle research:

• Lean body mass gain held at 1.5 kg across the 52-week period in continuous-treatment subjects.
• Subjects who discontinued at 26 weeks lost the lean-mass gain within 6 months, confirming dependence on ongoing GH/IGF-1 stimulation.
• IGF-1 elevation persisted at 52 weeks without escape, meaning pituitary downregulation did not occur.
• Muscle attenuation on CT improved (denser muscle, lower intramyocellular lipid).

The Stanley data answer a question researchers commonly ask: does the muscle effect plateau or fade? The answer is neither — it stabilises and persists as long as the GHRH stimulus continues. This is unlike many anabolic interventions where receptor downregulation erodes the effect.

Tesamorelin vs Direct GH Administration on Muscle

For muscle endpoints, how does tesamorelin actually compare with injecting recombinant human GH directly? The honest comparison:

The trade is real. Direct GH produces roughly 2× the absolute lean-mass gain at the cost of supraphysiological IGF-1, insulin resistance, and the classical GH side-effect cluster. Tesamorelin produces a smaller but cleaner anabolic effect because endogenous pulsatile GH release maintains intact negative feedback (somatostatin still works). For research models where you want to interrogate the IGF-1 axis without scrambling glucose homeostasis, tesamorelin is the better tool.

What Drives the Anabolic Effect — Mechanism in Detail

Three parallel mechanisms account for tesamorelin’s muscle effects:

1. Hepatic IGF-1. The principal pathway. Each tesamorelin-induced GH pulse triggers hepatic IGF-1 transcription. Circulating IGF-1 binds skeletal-muscle IGF-1R, activating PI3K/Akt/mTOR and biasing protein balance toward synthesis.
2. Local muscle IGF-1 (MGF splice variant). GH also induces local IGF-1 production within muscle, including the mechano-growth factor (MGF) splice variant that is particularly potent at satellite-cell activation (Klausen 2000).
3. Lipolysis-mediated substrate shift. GH’s lipolytic action on adipocytes increases free fatty acid availability, sparing amino acids from oxidation and freeing them for protein synthesis. This is a small but real contribution.

For comparison studies of related GHRH and GH-secretagogue peptides, see our ipamorelin vs CJC-1295 comparison.

Dosing Used in the Muscle-Mass Trials

Every published lean-mass dataset for tesamorelin used the same protocol:

• 2 mg subcutaneously, once daily, administered in the abdomen.
• Evening dosing preferred to align induced GH pulse with the natural nocturnal pulse window.
• Storage: reconstituted vial refrigerated, discarded after the labelled stability period.
• Reconstitution: 2 mg dose typically drawn from a 5 mg vial reconstituted with bacteriostatic water; concentration chosen to deliver 2 mg in a small (0.2–0.4 mL) injection volume.

Researchers experimenting with split AM/PM dosing or alternate-day protocols have anecdotally reported preserved IGF-1 elevation, but no peer-reviewed trial has formally tested those schedules for muscle endpoints. The Falutz/Stanley evidence base stands on once-daily 2 mg.

Where to Buy Tesamorelin in the UAE — 24h Delivery

REVIVE Peptides operates a cold-chain warehouse in Dubai stocking tesamorelin 5 mg and 10 mg vials. Both strengths ship with batch-specific HPLC certificates of analysis. Bacteriostatic water 3 mL is available as an add-on.

Ordering process

1. Place the order through the tesamorelin product page.
2. Pay by card or bank transfer; cash on delivery is available across all seven emirates.
3. Same-day Dubai orders dispatch within 2 hours of payment confirmation.
4. Cold-chain courier delivers in an insulated cooler with two frozen gel packs sufficient for the UAE summer transit window.
5. Refrigerate the lyophilised vial on arrival; it remains stable at 2–8°C and protected from light.

REVIVE keeps live tesamorelin stock in the UAE — the inventory page shows real-time vial counts so you can confirm availability before ordering. For multi-vial protocols (typical for 26-week or 52-week lean-mass studies), the bulk pricing tier applies from 10 vials.

Combining Tesamorelin With Other Peptides for Muscle Research

Researchers frequently pair tesamorelin with peptides that act on complementary anabolic or recovery pathways. The most studied pairings:

• Tesamorelin + BPC-157. BPC-157 supports tendon and connective-tissue adaptation while the IGF-1 axis drives muscle protein accretion (Sikiric 2010). See our BPC-157 tendon research notes.
• Tesamorelin + MOTS-c. MOTS-c improves mitochondrial substrate handling (Lee 2015), useful in models pairing anabolic stimulus with metabolic adaptation.
• Tesamorelin + TB-500. TB-500 (thymosin beta-4) modulates actin dynamics in healing tissue, complementing IGF-1-driven hypertrophy in injury-recovery models.

UAE-Specific Storage and Handling Notes

• Lyophilised vials are stable at 2–8°C. The UAE ambient temperature in summer (often 42°C+) makes reliable cold-chain mandatory.
• Reconstituted vials must be refrigerated. Once mixed with bacteriostatic water, treat the vial as a 28-day refrigerated reagent at most.
• Avoid direct sunlight. Tesamorelin is photosensitive; the amber vial protects against this but storage in a dark fridge compartment is best.
• Plan deliveries around extreme heat days. REVIVE’s Dubai dispatch uses pre-frozen gel packs validated for <8°C internal temperature across the standard same-day window.

Practical Takeaways for the Muscle-Mass Research Model

1. Tesamorelin produces a real but modest lean-mass effect (~1.0–1.5 kg in 26–52 weeks) driven by IGF-1.
2. The effect is dependent on continuous administration — it reverses on discontinuation.
3. Compared with direct rhGH, tesamorelin yields roughly half the absolute lean gain but preserves pituitary feedback and produces less insulin resistance and oedema.
4. Once-daily 2 mg SC is the only protocol with robust peer-reviewed lean-mass data.
5. For UAE-based researchers, cold-chain logistics are the rate-limiting factor — REVIVE’s Dubai stock with 24h emirate-wide delivery removes the import-customs bottleneck most international suppliers cannot bypass.